The OPTIMA (Optimal Personalized Treatment of Early Breast Cancer Using Multi-Parameter Analysis) de-escalation, partially blinded, clinical trial will evaluate the ability of the Prosigna PAM50 test to tailor adjuvant therapy for HR+/HER2− high-clinical risk BC patients [22]. Here, HR is linked to breast cancer.